Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours

Everolimus displays antiproliferative effects on cancer cells, yields antiangiogenic activity in established tumours, and shows synergistic activity with paclitaxel in preclinical models. This study assessed the safety and the pharmacokinetic interactions of everolimus and paclitaxel in patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Campone, M, Levy, V, Bourbouloux, E, Berton Rigaud, D, Bootle, D, Dutreix, C, Zoellner, U, Shand, N, Calvo, F, Raymond, E
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2634724/
https://www.ncbi.nlm.nih.gov/pubmed/19127256
http://dx.doi.org/10.1038/sj.bjc.6604851

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2634724/
https://www.ncbi.nlm.nih.gov/pubmed/19127256
http://dx.doi.org/10.1038/sj.bjc.6604851

Ejemplares similares